SCN1A and Dravet syndrome: Most of our analyses were performed following CAV-SCN1A administration at the onset of spontaneous seizures (P21; Figures 6–9), and the therapeutic potential in older mice during the chronic stage of DS was evaluated only following injection into the hippocampus (P35; Figure 5).